DPP4i treatment made simple.


TRAJENTA® (linagliptin) belongs to the DPP4 inhibitor (DPP4i) class of oral anti-diabetic medications1

DPP4i work by prolonging the action of the incretins GLP-1 and GIP to:1,2

Blue arrow
Increase glucose dependent
insulin secretion
leading to
increased glucose utilisation
by muscle and adipose tissue
Yellow arrow
Increase glucose dependent glucagon suppression leading to decreased hepatic glucose release which improves overall glucose control
GLP-1: Glucagon-like peptide 1;
GIP: Glucose dependent insulinotropic polypeptide.

Thanks to this mode of action, DPP4i are generally associated with:3

TRAJENTA® (linagliptin) proven efficacy on HbA1C
TRAJENTA® presents a very low risk for hypoglycaemia
TRAJENTA® DPP4i are generally associated with favourable safety and tolerability profile